The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Till death do us part: Existential loneliness (EL), psychosocial distress, and survival of advanced cancer patients (ACPs), and their spousal caregivers (SCs).
 
Fay J. Hlubocky
No Relationships to Disclose
 
Tamara Sher
No Relationships to Disclose
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Actinium Pharmaceuticals; Astellas Pharma; Bristol-Myers Squibb; Corcept Therapeutics; GlaxoSmithKline; HERON; IDDI; Novartis; Pfizer; PledPharma
Research Funding - Abbvie (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); PledPharma (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Ipsen; PledPharma
 
Mark J. Ratain
Stock and Other Ownership Interests - Biscayne Neurosciences
Consulting or Advisory Role - Aptevo Therapeutics; Ascentage Pharma; Cyclacel
Research Funding - Abbvie (Inst); Dicerna (Inst); Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - pending patent related to a genomic prescribing system; pending patent related to a genomic prescribing system (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - multiple generic companies
Other Relationship - Value in Cancer Care Consortium
 
Christopher Daugherty
Consulting or Advisory Role - Daiichi Sankyo